Oct 2026· Frontiers in Immunology· Vol 17· 0 citations· 4 references
Medicine
TL;DR
This Research Topic set out to examine immune and stromal mechanisms of chemoresistance, useful biomarkers, and improve combination treat-ment, and addresses different parts of that problem, from tumor-cell survival to drug delivery, response, and toxicity.
Abstract
Chemotherapy and immune checkpoint blockade act on the same changing tissue. Cytotoxic treatment selects the cells that survive and alters the signals they send to neighboring immune and stromal cells. Immune pressure, in turn, shapes which tumor cells persist. The clinical task is to learn when this interaction can be altered, in which patients, and at what cost. Trials in advanced gastric and gastroesophageal cancer show that adding PD-1 blockade to chemotherapy can prolong survival, while the size of the bene fi t varies across patients (1, 2). This Research Topic set out to examine immune and stromal mechanisms of chemoresistance, fi nd useful biomarkers, and improve combination treat-ment. Its papers address different parts of that problem, from tumor-cell survival to drug delivery, response, and toxicity. Most concern digestive cancers; their lessons for other solid tumors need testing.
This review summarizes the main immunotherapeutic approaches currently investigated, including immune checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, and oncolytic viruses, and examines the key biological factors responsible for treatment resistance.
D. Slavkov, S. Troyanova-Slavkova· Cancer Immunology Connect· 0 citations
Evidence that agents capable of inducing ICD may instead promote cellular senescence when administered at lower concentrations for prolonged periods is highlighted, indicating that these distinct cellular outcomes can be determined by drug dose and treatment duration.
Seong-Ah Shin, Minji Kim, Moonsu Kim et al.· Life· 0 citations
Esophageal carcinoma (EC) remains one of the most lethal malignancies, with a five-year survival rate of only 15-25% in advanced stages. Although immunotherapy including immune checkpoint inhibitors (ICIs) and antibody-based therapies have improved clinical outcomes, durable responses are confined to a minority of pati...
Zheng-Lin He, Han-Ming Hao, Xin-Yang Shu et al.· Frontiers in Immunology· 0 citations
Immune checkpoint inhibitors have improved outcomes in selected patients with breast cancer, particularly those with triple-negative disease, but most tumors remain refractory. Abnormal tumor vasculature is one contributor to this resistance. Disorganized, hyperpermeable vessels produce heterogeneous perfusion, hypoxia...
Yu-Jin Zhang, Yu-Lan Cai, Kai-Guo Long et al.· Frontiers in Oncology· 0 citations
Gastric cancer remains one of the leading causes of cancer-related death worldwide, with particularly high incidence in East Asia. Despite improvements in surgical resection and perioperative chemotherapy, patients with advanced or metastatic disease face a poor prognosis. The arrival of ICIs, especially anti-PD-1 anti...
Hao Yuan, Nan Li, Huai-Jue Qiu et al.· Frontiers in Immunology· 0 citations
Understanding the interplay between immune and stromal cells in the tumor microenvironment is essential for developing effective cancer therapies and preventing relapses. In this review, starting with the basics of tumor immunology and a historical review from cancer chemotherapy to current immunotherapy, in the contex...
Adrián Povo-Retana, Javier Ruiz-Navarro, Lucía Fernández-Frías et al.· International Journal of Mol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.